在健康的老年人中,GABA+和Glx度与年龄和抑制之间的关系
Ciara Treacy1, Sophie C Andrews2, Jacob M Levenstein2
1Thompson Institute, University of the Sunshine Coast, 12 Innovation Pathway, Birtinya, QLD, 4575, Australia. ctreacy@usc.edu.au.
Brain structure & function
|September 27, 2025
概括
这项研究发现,虽然衰老不会显著改变大脑神经化学水平 (GABA+和Glx),但在感觉运动皮质中较高的Glx会改善抑制控制,这表明质质系统在抑制反应中发挥了作用,无论年龄如何.
科学领域:
- 神经科学是一个神经科学.
- 认知老龄化 认知老龄化
- 神经化学 神经化学
背景情况:
- 抑制是一种关键的执行功能,对于抑制分心至关重要.
- 衰老对抑制控制的影响和神经化学物质GABA (胺黄油酸) 和Glx (谷氨酸+谷氨胺) 等神经化学物质的作用尚不清楚.
- 神经可塑性受到这些神经化学物质的影响,是衰老期间认知功能的核心.
研究的目的:
- 为了研究健康衰老中GABA+和Glx度与年龄相关的变化.
- 探索这些神经化学物质与特定抑制子成分之间的关联.
- 了解老年人抑制控制的神经化学基础.
主要方法:
- 参与者 (SM1中的N=71,PFC中的N=58) 接受了磁共振光谱 (MRS) 来测量GABA+和Glx.
- 通过使用三个任务来评估抑制功能:侧翼者,Stroop和go/no-go.
- 统计分析包括半部分和部分相关性,对年龄,性别和教育进行控制.
主要成果:
- 在传感运动 (SM1) 或前额叶皮层 (PFC) 的GABA+或Glx度中没有发现与年龄相关的显著差异.
- 在SM1中,较高的Glx度显著与去/不去任务中的错误减少有关,这表明更好的响应抑制.
- 这些发现表明神经化学物质度可能不会随着年龄的增长而均下降,并突出显示了谷氨酸酶系统在抑制中的作用.
结论:
- 健康老龄化可能不包括GABA+和Glx的均下降,这表明关系更复杂.
- 感觉运动皮层 Glx 度与不依赖年龄的改善反应抑制有关.
- 谷氨酸酶系统在支持抑制控制方面发挥着作用,为认知衰老和神经可塑性提供了洞察力.
关键词:
对于GABA来说,这是一个很好的选择.Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx Glx健康的老龄化 健康的老龄化抑制抑制的抑制作用这就是MRS MRS.磁共振光谱学 磁共振光谱学更多相关视频
07:51Inhibitory Synapse Formation in a Co-culture Model Incorporating GABAergic Medium Spiny Neurons and HEK293 Cells Stably Expressing GABAA Receptors
Published on: November 14, 2014
17.8K
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
14.1K
相关概念视频
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
172
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
214
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
214
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
201
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
201
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
200
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
200
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
176
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
176
01:15Drug Dosing: Geriatric Patients
199
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199